Toolkit/H3K36me3 cell-free chromatin immunoprecipitation sequencing

H3K36me3 cell-free chromatin immunoprecipitation sequencing

Assay Method·Research·Since 2024

Also known as: cfChIP-seq

Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.

Summary

H3K36me3 cell-free chromatin immunoprecipitation sequencing (cfChIP-seq) is a plasma-based assay that establishes a personal gene expression profile from cell-free chromatin. In the cited study context, it functions as a reference enrichment assay for active genes in liquid biopsy samples.

Usefulness & Problems

Why this is useful

This assay is useful for inferring active gene expression programs from plasma-derived cell-free chromatin without direct tissue sampling. The cited work uses H3K36me3 cfChIP-seq as a benchmark for enrichment of highly expressed genes in liquid biopsy analyses.

Problem solved

It addresses the problem of obtaining gene expression-related information from blood-based cell-free material. Specifically, it provides a reference method for identifying active genes in plasma samples through H3K36me3-associated chromatin enrichment.

Problem links

Need better screening or enrichment leverage

Derived

H3K36me3 cell-free chromatin immunoprecipitation sequencing (cfChIP-seq) is a plasma-based assay that establishes a personal gene expression profile from cell-free chromatin. In the cited study context, it functions as a reference enrichment assay for active genes in liquid biopsy samples.

Taxonomy & Function

Primary hierarchy

Technique Branch

Method: A concrete measurement method used to characterize an engineered system.

Target processes

selection

Implementation Constraints

cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor

The assay is performed on plasma and uses immunoprecipitation of cell-free chromatin marked by H3K36me3 followed by sequencing-based readout. The supplied evidence does not provide details on antibody reagents, library preparation, sequencing depth, or bioinformatic processing.

The provided evidence does not report analytical sensitivity, specificity, input requirements, reproducibility, or performance across diseases and cohorts. The claims about fragment length and end motifs are associative and come from a single cited study context rather than direct broad validation of the assay itself.

Validation

Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication

Supporting Sources

Ranked Claims

Claim 1associationsupports2024Source 1needs review

Distinct GC-rich fragment end motifs are enriched after cfChIP.

Furthermore, distinct GC-rich FEMs were enriched after cfChIP.
Claim 2associationsupports2024Source 1needs review

Distinct GC-rich fragment end motifs are enriched after cfChIP.

Furthermore, distinct GC-rich FEMs were enriched after cfChIP.
Claim 3associationsupports2024Source 1needs review

Distinct GC-rich fragment end motifs are enriched after cfChIP.

Furthermore, distinct GC-rich FEMs were enriched after cfChIP.
Claim 4associationsupports2024Source 1needs review

Distinct GC-rich fragment end motifs are enriched after cfChIP.

Furthermore, distinct GC-rich FEMs were enriched after cfChIP.
Claim 5associationsupports2024Source 1needs review

Distinct GC-rich fragment end motifs are enriched after cfChIP.

Furthermore, distinct GC-rich FEMs were enriched after cfChIP.
Claim 6associationsupports2024Source 1needs review

Distinct GC-rich fragment end motifs are enriched after cfChIP.

Furthermore, distinct GC-rich FEMs were enriched after cfChIP.
Claim 7associationsupports2024Source 1needs review

Distinct GC-rich fragment end motifs are enriched after cfChIP.

Furthermore, distinct GC-rich FEMs were enriched after cfChIP.
Claim 8associationsupports2024Source 1needs review

Genes with the highest expression are enriched for short cfDNA fragments compared with genes with low expression.

The genes with the highest expression displayed an enrichment of short cfDNA fragments (median = 19.99%, IQR: 16.94-27.13%, p < 0.0001) compared to the genes with low expression.
p value 0.0001short cfDNA fragment enrichment among highest-expression genes 19.99 %short cfDNA fragment enrichment among highest-expression genes 16.94-27.13 %
Claim 9associationsupports2024Source 1needs review

Genes with the highest expression are enriched for short cfDNA fragments compared with genes with low expression.

The genes with the highest expression displayed an enrichment of short cfDNA fragments (median = 19.99%, IQR: 16.94-27.13%, p < 0.0001) compared to the genes with low expression.
p value 0.0001short cfDNA fragment enrichment among highest-expression genes 19.99 %short cfDNA fragment enrichment among highest-expression genes 16.94-27.13 %
Claim 10associationsupports2024Source 1needs review

Genes with the highest expression are enriched for short cfDNA fragments compared with genes with low expression.

The genes with the highest expression displayed an enrichment of short cfDNA fragments (median = 19.99%, IQR: 16.94-27.13%, p < 0.0001) compared to the genes with low expression.
p value 0.0001short cfDNA fragment enrichment among highest-expression genes 19.99 %short cfDNA fragment enrichment among highest-expression genes 16.94-27.13 %
Claim 11associationsupports2024Source 1needs review

Genes with the highest expression are enriched for short cfDNA fragments compared with genes with low expression.

The genes with the highest expression displayed an enrichment of short cfDNA fragments (median = 19.99%, IQR: 16.94-27.13%, p < 0.0001) compared to the genes with low expression.
p value 0.0001short cfDNA fragment enrichment among highest-expression genes 19.99 %short cfDNA fragment enrichment among highest-expression genes 16.94-27.13 %
Claim 12associationsupports2024Source 1needs review

Genes with the highest expression are enriched for short cfDNA fragments compared with genes with low expression.

The genes with the highest expression displayed an enrichment of short cfDNA fragments (median = 19.99%, IQR: 16.94-27.13%, p < 0.0001) compared to the genes with low expression.
p value 0.0001short cfDNA fragment enrichment among highest-expression genes 19.99 %short cfDNA fragment enrichment among highest-expression genes 16.94-27.13 %
Claim 13associationsupports2024Source 1needs review

Genes with the highest expression are enriched for short cfDNA fragments compared with genes with low expression.

The genes with the highest expression displayed an enrichment of short cfDNA fragments (median = 19.99%, IQR: 16.94-27.13%, p < 0.0001) compared to the genes with low expression.
p value 0.0001short cfDNA fragment enrichment among highest-expression genes 19.99 %short cfDNA fragment enrichment among highest-expression genes 16.94-27.13 %
Claim 14associationsupports2024Source 1needs review

Genes with the highest expression are enriched for short cfDNA fragments compared with genes with low expression.

The genes with the highest expression displayed an enrichment of short cfDNA fragments (median = 19.99%, IQR: 16.94-27.13%, p < 0.0001) compared to the genes with low expression.
p value 0.0001short cfDNA fragment enrichment among highest-expression genes 19.99 %short cfDNA fragment enrichment among highest-expression genes 16.94-27.13 %
Claim 15integration benefitsupports2024Source 1needs review

Combining short cfDNA fragment frequency with distinct fragment end motifs further enriches for the most expressed genes.

Combining the frequency of short cfDNA fragments with the presence of distinct FEMs resulted in an even further enrichment of the most expressed genes (median = 37.85%, IQR: 30.10-39.49%, p < 0.0001).
combined-feature enrichment of most expressed genes 37.85 %combined-feature enrichment of most expressed genes 30.10-39.49 %p value 0.0001
Claim 16integration benefitsupports2024Source 1needs review

Combining short cfDNA fragment frequency with distinct fragment end motifs further enriches for the most expressed genes.

Combining the frequency of short cfDNA fragments with the presence of distinct FEMs resulted in an even further enrichment of the most expressed genes (median = 37.85%, IQR: 30.10-39.49%, p < 0.0001).
combined-feature enrichment of most expressed genes 37.85 %combined-feature enrichment of most expressed genes 30.10-39.49 %p value 0.0001
Claim 17integration benefitsupports2024Source 1needs review

Combining short cfDNA fragment frequency with distinct fragment end motifs further enriches for the most expressed genes.

Combining the frequency of short cfDNA fragments with the presence of distinct FEMs resulted in an even further enrichment of the most expressed genes (median = 37.85%, IQR: 30.10-39.49%, p < 0.0001).
combined-feature enrichment of most expressed genes 37.85 %combined-feature enrichment of most expressed genes 30.10-39.49 %p value 0.0001
Claim 18integration benefitsupports2024Source 1needs review

Combining short cfDNA fragment frequency with distinct fragment end motifs further enriches for the most expressed genes.

Combining the frequency of short cfDNA fragments with the presence of distinct FEMs resulted in an even further enrichment of the most expressed genes (median = 37.85%, IQR: 30.10-39.49%, p < 0.0001).
combined-feature enrichment of most expressed genes 37.85 %combined-feature enrichment of most expressed genes 30.10-39.49 %p value 0.0001
Claim 19integration benefitsupports2024Source 1needs review

Combining short cfDNA fragment frequency with distinct fragment end motifs further enriches for the most expressed genes.

Combining the frequency of short cfDNA fragments with the presence of distinct FEMs resulted in an even further enrichment of the most expressed genes (median = 37.85%, IQR: 30.10-39.49%, p < 0.0001).
combined-feature enrichment of most expressed genes 37.85 %combined-feature enrichment of most expressed genes 30.10-39.49 %p value 0.0001
Claim 20integration benefitsupports2024Source 1needs review

Combining short cfDNA fragment frequency with distinct fragment end motifs further enriches for the most expressed genes.

Combining the frequency of short cfDNA fragments with the presence of distinct FEMs resulted in an even further enrichment of the most expressed genes (median = 37.85%, IQR: 30.10-39.49%, p < 0.0001).
combined-feature enrichment of most expressed genes 37.85 %combined-feature enrichment of most expressed genes 30.10-39.49 %p value 0.0001
Claim 21integration benefitsupports2024Source 1needs review

Combining short cfDNA fragment frequency with distinct fragment end motifs further enriches for the most expressed genes.

Combining the frequency of short cfDNA fragments with the presence of distinct FEMs resulted in an even further enrichment of the most expressed genes (median = 37.85%, IQR: 30.10-39.49%, p < 0.0001).
combined-feature enrichment of most expressed genes 37.85 %combined-feature enrichment of most expressed genes 30.10-39.49 %p value 0.0001
Claim 22method performancesupports2024Source 1needs review

In vitro size selection of <150 bp cfDNA can isolate cfDNA representing active genes, and the enrichment correlates with cfChIP-seq enrichment.

An in vitro size selection of <150 bp cfDNA could isolate cfDNA representing active genes and the size-selection enrichment correlated with the cfChIP-seq enrichment (Spearman r range: 0.499-0.882, p < 0.0001).
p value 0.0001Spearman correlation with cfChIP-seq enrichment 0.499-0.882
Claim 23method performancesupports2024Source 1needs review

In vitro size selection of <150 bp cfDNA can isolate cfDNA representing active genes, and the enrichment correlates with cfChIP-seq enrichment.

An in vitro size selection of <150 bp cfDNA could isolate cfDNA representing active genes and the size-selection enrichment correlated with the cfChIP-seq enrichment (Spearman r range: 0.499-0.882, p < 0.0001).
p value 0.0001Spearman correlation with cfChIP-seq enrichment 0.499-0.882
Claim 24method performancesupports2024Source 1needs review

In vitro size selection of <150 bp cfDNA can isolate cfDNA representing active genes, and the enrichment correlates with cfChIP-seq enrichment.

An in vitro size selection of <150 bp cfDNA could isolate cfDNA representing active genes and the size-selection enrichment correlated with the cfChIP-seq enrichment (Spearman r range: 0.499-0.882, p < 0.0001).
p value 0.0001Spearman correlation with cfChIP-seq enrichment 0.499-0.882
Claim 25method performancesupports2024Source 1needs review

In vitro size selection of <150 bp cfDNA can isolate cfDNA representing active genes, and the enrichment correlates with cfChIP-seq enrichment.

An in vitro size selection of <150 bp cfDNA could isolate cfDNA representing active genes and the size-selection enrichment correlated with the cfChIP-seq enrichment (Spearman r range: 0.499-0.882, p < 0.0001).
p value 0.0001Spearman correlation with cfChIP-seq enrichment 0.499-0.882
Claim 26method performancesupports2024Source 1needs review

In vitro size selection of <150 bp cfDNA can isolate cfDNA representing active genes, and the enrichment correlates with cfChIP-seq enrichment.

An in vitro size selection of <150 bp cfDNA could isolate cfDNA representing active genes and the size-selection enrichment correlated with the cfChIP-seq enrichment (Spearman r range: 0.499-0.882, p < 0.0001).
p value 0.0001Spearman correlation with cfChIP-seq enrichment 0.499-0.882
Claim 27method performancesupports2024Source 1needs review

In vitro size selection of <150 bp cfDNA can isolate cfDNA representing active genes, and the enrichment correlates with cfChIP-seq enrichment.

An in vitro size selection of <150 bp cfDNA could isolate cfDNA representing active genes and the size-selection enrichment correlated with the cfChIP-seq enrichment (Spearman r range: 0.499-0.882, p < 0.0001).
p value 0.0001Spearman correlation with cfChIP-seq enrichment 0.499-0.882
Claim 28method performancesupports2024Source 1needs review

In vitro size selection of <150 bp cfDNA can isolate cfDNA representing active genes, and the enrichment correlates with cfChIP-seq enrichment.

An in vitro size selection of <150 bp cfDNA could isolate cfDNA representing active genes and the size-selection enrichment correlated with the cfChIP-seq enrichment (Spearman r range: 0.499-0.882, p < 0.0001).
p value 0.0001Spearman correlation with cfChIP-seq enrichment 0.499-0.882

Approval Evidence

1 source3 linked approval claimsfirst-pass slug h3k36me3-cell-free-chromatin-immunoprecipitation-sequencing
A personal gene expression profile was established from plasma using H3K36me3 cell-free chromatin immunoprecipitation sequencing (cfChIP-seq).

Source:

associationsupports

Distinct GC-rich fragment end motifs are enriched after cfChIP.

Furthermore, distinct GC-rich FEMs were enriched after cfChIP.

Source:

integration benefitsupports

Combining short cfDNA fragment frequency with distinct fragment end motifs further enriches for the most expressed genes.

Combining the frequency of short cfDNA fragments with the presence of distinct FEMs resulted in an even further enrichment of the most expressed genes (median = 37.85%, IQR: 30.10-39.49%, p < 0.0001).

Source:

method performancesupports

In vitro size selection of <150 bp cfDNA can isolate cfDNA representing active genes, and the enrichment correlates with cfChIP-seq enrichment.

An in vitro size selection of <150 bp cfDNA could isolate cfDNA representing active genes and the size-selection enrichment correlated with the cfChIP-seq enrichment (Spearman r range: 0.499-0.882, p < 0.0001).

Source:

Comparisons

Source-backed strengths

The supplied evidence shows that H3K36me3 cfChIP-seq can establish a personal gene expression profile from plasma. In the associated study, cfChIP-enriched material also showed distinct GC-rich fragment end motifs, and the assay context supported enrichment of highly expressed genes.

H3K36me3 cell-free chromatin immunoprecipitation sequencing and open-source microplate reader address a similar problem space because they share selection.

Shared frame: same top-level item type; shared target processes: selection

Strengths here: looks easier to implement in practice.

Compared with STED microscopy

H3K36me3 cell-free chromatin immunoprecipitation sequencing and STED microscopy address a similar problem space because they share selection.

Shared frame: same top-level item type; shared target processes: selection

H3K36me3 cell-free chromatin immunoprecipitation sequencing and touchscreen-equipped operant conditioning chambers address a similar problem space because they share selection.

Shared frame: same top-level item type; shared target processes: selection

Ranked Citations

  1. 1.
    StructuralSource 1International Journal of Molecular Sciences2024Claim 1Claim 2Claim 3

    Extracted from this source document.